The drug you throw away is still revenue, if you tag it right.
Here is the short answer. When you draw a single-dose vial and discard the leftover, modifier JW bills Medicare for the wasted amount. When nothing is discarded, modifier JZ is the mandatory attestation that says so. Report one or the other on every single-dose drug line, every time. Skip it and you either leave money on the table or hand an auditor a reason to knock.
The rules in four numbers
What a chemotherapy practice is actually accountable for
These are not soft targets. Each one is written into current CMS discarded-drug policy or the CMMI oncology model your infusion suite may already be reporting into.
The core distinction
JW pays you. JZ protects you.
Same policy, opposite jobs. Confusing the two is the single most common wastage error we see in oncology charts.
JW
Reports the amount of a drug or biological from a single-dose vial or single-use package that was discarded. It is a separate billed line for the wasted units.
- Bill the administered amount on one line, the discarded amount on a second line with JW appended.
- Applies only to single-dose containers, never to multi-dose vials.
- The discard must be documented in the medical record: drug, dose given, amount wasted, and why.
JZ
Attests that zero amount was discarded from a single-dose container. It is not paid, but it is required, and it is enforced by claim edits.
- Use when the full vial contents were administered with nothing left over.
- Mandatory since July 1, 2023 on single-dose-container drugs when no JW applies.
- Its real value is defensive: a JZ says you looked at wastage and confirmed there was none.
One line, one decision
The rule your infusion team can run in five seconds
If it is multi-dose, JW and JZ do not apply.
Compare vial size to dose given.
Side by side
When each modifier belongs on the claim
| Scenario | Container | Discarded? | Modifier | Pays? |
|---|---|---|---|---|
| Weight-based dose, partial vial used | Single-dose vial | Yes | JW on discard line | Yes |
| Full vial administered, nothing left | Single-dose vial | No | JZ | No, attestation |
| Drug drawn from a shared multi-dose vial | Multi-dose vial | Not applicable | Neither | Standard units only |
| Vial contaminated before use, full waste | Single-dose vial | Yes, document reason | JW | Per payer policy |
| Single-dose line, no modifier at all | Single-dose vial | Unknown | Edit risk | Line may deny |
ASCO coding guidance echoes this: report JW for the discarded portion of single-use packaging and JZ when there is none, and keep the wastage documentation tight enough to survive a look-back.
Two sides of the same coin
Why the same modifier drives both revenue and risk
The audit exposure
High-cost oncology drugs make wastage lines a natural audit target. A JW line billed without a documented discard reason, or a pattern of implausible waste on a single-dose drug, is exactly what post-payment review looks for.
Every JW line needs a record
Drug, dose administered, amount discarded, and clinical reason. The modifier is a claim; the chart is the proof. The manufacturer refund provision for discarded amounts, created under the Infrastructure Investment and Jobs Act, means CMS is already watching this data closely.
The Enhancing Oncology Model tie-in
If your practice participates in the CMMI Enhancing Oncology Model, drug spend and total cost of care feed your performance benchmark. Clean JW and JZ reporting is not just per-claim revenue, it shapes the numbers your MEOS payments and reconciliation are measured against.
$70 PBPM MEOS, plus reconciliation
The Model runs through June 2030, so sloppy wastage capture quietly distorts a benchmark you live with for years.
Guidelines referenced
- CMS, Discarded Drugs and Biologicals modifier policy (JW required for discarded single-dose amounts; JZ required to attest no discarded amount, effective July 1, 2023), including MLN Matters MM12780.
- CMS Innovation Center (CMMI), Enhancing Oncology Model, including the Monthly Enhanced Oncology Services (MEOS) payment and the July 2023 through June 2030 performance period.
- Section 90004 of the Infrastructure Investment and Jobs Act, discarded-drug manufacturer refund provision, which relies on JW and JZ claims data.
- American Society of Clinical Oncology (ASCO) coding and billing guidance on JW and JZ modifiers and drug-wastage documentation.
Turn discarded drug into documented revenue.
ASP-RCM Solutions runs oncology billing where JW, JZ, and EOM reporting are handled as one clean workflow: every single-dose line modified, every discard documented, every audit look-back defensible. If your wastage capture is a guess right now, we will make it a system.
Related reading
Modifiers 24, 25, and 57 in the 2026 Global Period
A side-by-side comparison of modifiers 24, 25, and 57 in the 2026 global period, built for orthopedic practice
Read →WhitepaperThree code stacks, one patient. Pick the right one before you build the claim.
A side-by-side 2026 matrix comparing Collaborative Care (99492-99494, G2214), general Behavioral Health Integr
Read →Field noteWho Gets Billing Credit When a Physician and an APP Share the Visit
Who gets billing credit when a physician and an APP share a visit under the CMS CY2026 Physician Fee Schedule.
Read →